
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a promising U.S.-based epigenetics company with a novel Nucleosomics platform and strong focus on human diagnostics. The recent proof of concept data from a blinded validation cohort for the detection of early stage cancers using its Capture-Seq technology is highly encouraging, and if validated in larger cohorts, could potentially be used for Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) detection and treatment monitoring. The company is also in discussions with several leading diagnostic and liquid biopsy companies and may secure additional licensing deals in 2026, which could drive continued revenue growth.
Bears say
VolitionRX is a company that focuses on developing cost-effective blood tests for disease detection, including cancers and other life-altering conditions. While the company's Nucleosomics platform has shown potential in identifying and monitoring diseases, VolitionRX's financial risk and market share risk, coupled with the limited tools for risk stratification in the field, make the company's prospects uncertain. Additionally, while the recent Mayo Clinic study adds to the clinical validation of the platform, there is limited evidence of its effectiveness in real-world settings.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares